Champions TumorGrafts Guide the Development of a Novel, Selective Dual BRAF/EGFR Inhibitor, CEP-32496
Identifying and developing targeted oncology compounds is often an arduous, costly and time-consuming process.
As the demand for effective personalized oncology therapies grow, so does the need for a more predictive model solution.
Champions Oncology’s predictive patient-derived xenograft (PDX) models, Champions TumorGrafts, helps bridge the translational gap in oncology drug development by providing a highly-focused and accelerated simulated clinical trial.
The value of Champions TumorGrafts are demonstrated in our latest case study, which shows how the utilization of our PDX models in a screening and efficacy evaluation impacted the development of a novel compound, the dual BRAF-EGR inhibitor, CEP-32496.
Click here to download a pdf file of the case study:
Download the Case Study
December 15, 2014
Associated Press: Cancer Patients Testing Drugs on Mouse ‘Avatars’
October 1, 2014
MedPage Today: Patient-Derived Xenografts Accurately Capture Clinical Responses to Treatment
September 22, 2014
CTV News: ‘Precision Medicine’ Offers Hope for Liposarcoma Tumours
August 11, 2014
MIT Technology Review: A Mouse with the Same Cancer as You
June 13, 2014
Newsweek: The Perfect Drug
April 29, 2014
NBC News: Mouse Avatars Allow Cancer Patients to Test Cures
February 21, 2014
The Strait Times: Cancer Procedure Tested in Singapore May Lead to More Precise Treatments
February 13, 2014
Bloomberg BusinessWeek: Mouse Avatars for Testing Chemotherapy Drugs
April 18, 2013
National Post: Experimental Cancer Test Grafts Tumours into Mice to Create Customized Treatment
April 18, 2013
NBC New York: NJ Boy Battling Cancer May Have Found Breakthrough Treatment
September 25, 2012
New York Times: Seeking Cures, Patients Enlist Mice Stand-Ins